Tales from TCT 2019: Ancora ’s Heart Felt Data

A stronger and more experienced Ancora Heart entered into the 31st Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation this past week. The private company – which is poised to take on medtech giants Abbott Laboratories and Edwards Lifesciences in the functional mitral regurgitation (FMR) space, presented even more data than it did last year at TCT. “There’s a big presence for us this year [at TCT] with three different presentations,” Jeff Closs, president and CEO of Ancora Heart, told MD+DI. “It is different in a very positive way this year vs. last year. I think it has to do with a couple of things. We’re further in our enrollment. We have four centers and four physicians who have now implanted the device and seen the patient results.” The Santa Clara, CA-based company touted data from the CorCinch FMR study, a U.S. early feasibility study evaluating the safety of the investigational AccuCinch Ventricular Repair System designed for the treatment of systolic heart failure. Enrollment in the CorCinch FMR study recently concluded and 35 patients were treated with the AccuCinch at 15 heart centers. The primary safety endpoint of the study is device-related or procedure-related major adverse events through 30 days. Secondary exploratory endpoints include technical success, device and pr...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Business Source Type: news